Health
Immunotherapy extends survival in patients with advanced bladder cancer – News-Medical.Net
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Cent…

Reviewed by Emily Henderson, B.Sc.Sep 18 2020
An immunotherapy drug called ‘avelumab’ has been shown to significantly improve survival in patients with the most common type of bladder cancer, according to results from a phase III clinical trial led by Queen Mary University of London and Barts Cancer Centre, UK.
This is the first time an immune therapy has resulted in a survival advantage in this setting in bladder cancer, and will potentially benefit thousands of patients each year.
The resul…
-
Noosa News20 hours ago
NRL grand final quick hits: Reece Walsh creates magic after avoiding sin bin as Broncos survive Hunt, Reynolds injuries to win premiership
-
General19 hours ago
How the internet reacted to Brisbane Broncos winning the NRL grand final
-
Noosa News11 hours ago
New playground equipment encourages children to learn through ‘risky play’
-
General8 hours ago
Three youths in police custody after fire at Ashley Youth Detention Centre in northern Tasmania